David L. Lacey spent 17 years at Amgen, where he helped discover the OPG/RANKL/RANK pathway that led to denosumab and the bone-disease medicines Prolia and XGEVA, and later led a 1,200-scientist discovery organization across oncology, inflammation, metabolic disease, and neuroscience. He holds a biology degree and an M.D. from the University of Colorado and is board-certified in anatomic pathology, and boards like argenx, UNITY, and Inbiomotion have brought him on specifically for his R&D and drug-discovery judgment rather than for a typical investment background.
About their Fund
Ysios Capital is Spain's largest life sciences venture capital firm, with ties to Spain's science leadership through cofounder Cristina Garmendia, who left the firm to serve as Spain's Minister of Science and Innovation before returning as a partner, and it has moved beyond typical venture investing into company creation through its InceptionBio vehicle, which builds biotech companies from early tech-transfer projects with a strong focus on Spain. The firm focuses on hard science areas like gene therapy, oncology, orphan CNS disease, calcification disorders, and regenerative cardiovascular implants, has backed deals such as Sanifit's acquisition by Vifor Pharma and U.S.-based Kala Pharmaceuticals, and produced three NASDAQ IPOs in 2021 alongside its oversubscribed €216M third fund.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































